These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20946155)

  • 1. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.
    Watzka M; Geisen C; Bevans CG; Sittinger K; Spohn G; Rost S; Seifried E; Müller CR; Oldenburg J
    J Thromb Haemost; 2011 Jan; 9(1):109-18. PubMed ID: 20946155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
    Orsi FA; Annichino Bizzacchi JM; de Paula EV; Ozelo MC; Langley MR; Weck KE
    Thromb Res; 2010 Sep; 126(3):e206-10. PubMed ID: 20615525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
    Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
    Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
    Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
    Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.
    Lacut K; Ayme-Dietrich E; Gourhant L; Poulhazan E; Andro M; Becquemont L; Mottier D; Le Gal G; Verstuyft C
    Br J Clin Pharmacol; 2012 Mar; 73(3):428-36. PubMed ID: 21883387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
    Bodin L; Verstuyft C; Tregouet DA; Robert A; Dubert L; Funck-Brentano C; Jaillon P; Beaune P; Laurent-Puig P; Becquemont L; Loriot MA
    Blood; 2005 Jul; 106(1):135-40. PubMed ID: 15790782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.
    Molden E; Okkenhaug C; Ekker Solberg E
    Eur J Clin Pharmacol; 2010 May; 66(5):525-30. PubMed ID: 20354686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.
    Spreafico M; Lodigiani C; van Leeuwen Y; Pizzotti D; Rota LL; Rosendaal F; Mannucci PM; Peyvandi F
    Pharmacogenomics; 2008 Sep; 9(9):1237-50. PubMed ID: 18781852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
    Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
    Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
    Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
    Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
    Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
    J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.
    Djaffar-Jureidini I; Chamseddine N; Keleshian S; Naoufal R; Zahed L; Hakime N
    Genet Test Mol Biomarkers; 2011 Nov; 15(11):827-30. PubMed ID: 21651319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
    van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
    J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
    Verstuyft C; Delavenne X; Rousseau A; Robert A; Tod M; Diquet B; Lebot M; Jaillon P; Becquemont L
    Clin Pharmacokinet; 2012 Jan; 51(1):41-53. PubMed ID: 22149257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.